TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/07/2026
Back to search
Official data from USPTO
KD PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KD PHARMA
ST13
US500000097376275Class
1, 5, 29
Filing
97376275
Registration
7593034
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
01/09/2026
Trademark type
Word
Nice classes
1, 5, 29
Filing date
04/22/2022
Registration date
12/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/10/2024
Last transaction
01/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
16
Owner location
Bexbach, DE
Examiner
KEELEY,ALISON REBECCA
Law office
M40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
K.D. Pharma Bexbach GmbH
Representatives
KLAUS P. STOFFEL Lucas & Mercanti, LLP
Technical classification
Nice Classes
Class 1Class 5Class 29
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Oils and fatslipids used in the manufacture of cosmeticsbeveragesfood productspharmaceuticals and dietary supplements for the manufacture of pharmaceuticalsmedical and veterinary preparationssanitary preparations for medical purposesdietetic foodstuffs and products for medical or veterinary purposesfood supplements for humans and animalsmedicines and natural remediesdietetic preparations and food supplements and pharmaceutical preparations and substancesdietary supplements and dietetic preparationsfood for babies and infantsfor manufacturing beverages for infants and infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
Class 5
Pharmaceuticalmedical and veterinary preparationspharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorderspharmaceutical products for the prevention and treatment of cancerpharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorderspharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti-infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccineschemical reagents for medical or veterinary purposeschemical reagents for medical or veterinary purposes; sanitary preparations for medical purposes; dietetic foodstuffs and goods for medical or veterinary purposesdietetic foods and beverages adapted for medical usedietetic foods adapted for veterinary usedietetic beverages adapted for veterinary usedietetic preparations adapted for medical purposes; food supplements for humans and animals; disinfectants; medicines and natural remediesnamely medicinal oils and antiallergic medicinesmedicinal preparations for the treatment of infectious diseases and for use in oncologymedicinal drinksmedicinal preparations for infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disordersfor the prevention and treatment of cancerfor the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersfor the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria- based diseasesfor the treatment of epilepsypainanxietydepressionsleep disordersParkinson's diseasenausea and vomitingfood disordersarthritisPTSDschizophreniaopioid addictionalleviate ALS symptomsmultiple sclerosisfor the treatment of diabetesnatural remedy preparations for the treatment of gastro-intestinal conditionshormonal and chemical imbalancessleep disorders; dietetic preparationsnamely Dietetic preparations adapted for medical purposes; food supplements; food for babies; food for infants; infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
Class 29
Oils and fatsnamely edible oils and edible fats and oils and fats for food; dietetic oils and fats in the nature of edible oils and fatsnot for medical purposes; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
Publications
History of USPTO decisions and trademark events.
41 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/07/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/07/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/07/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/08/2024
PUBO
PUBLISHED FOR OPPOSITION
10/08/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/18/2024
EXPT
EXPARTE APPEAL TERMINATED
09/04/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/04/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
09/04/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/04/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
09/04/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/04/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
09/04/2024
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
07/01/2024
GNSF
SUBSEQUENT FINAL EMAILED
07/01/2024
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
07/01/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/04/2024
EXPI
EX PARTE APPEAL-INSTITUTED
06/04/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
06/04/2024
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
06/04/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
03/04/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
03/04/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/04/2023
GNFR
FINAL REFUSAL E-MAILED
12/04/2023
CNFR
FINAL REFUSAL WRITTEN
12/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/20/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
06/19/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
06/19/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/20/2023
GNRT
NON-FINAL ACTION E-MAILED
03/20/2023
CNRT
NON-FINAL ACTION WRITTEN
03/20/2023
DOCK
ASSIGNED TO EXAMINER
03/01/2023
DOCK
ASSIGNED TO EXAMINER
02/18/2023
DOCK
ASSIGNED TO EXAMINER
02/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/27/2022
NWAP
NEW APPLICATION ENTERED
04/26/2022
Continuous trademark protection
Get notified about every new filing that threatens KD PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.